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Intracellular oncotargetIt is commonly believed that antibodies are too large (150 kDa) to access the intracellular compart-
ment. Therefore, therapeutic antibodies have been traditionally used to target cell surface receptors
or soluble proteins in the circulation, leaving a large intracellular treasure of potential cancer-spe-
ciﬁc targets untapped. This review offers new perspectives on our recently proposed concept that
antibodies can be used to target intracellular tumor antigens for anti-cancer therapy. We propose
to vastly expand the repertoire of potential targets for cancer immunotherapy since many excellent
cancer targets are inside cells.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
1.1. The global commercial market for therapeutic antibodies
The vision of antibodies as ‘magic bullets’ that could be used to
selectively target disease-causing organisms was ﬁrst proposed by
Paul Ehrlich more than a century ago [1]. With the emphasis and
recent success on personalized medicine and drug speciﬁcity,
monoclonal antibodies (mAbs) are one of the largest classes of
drugs today and have been very commercially successful. Because
antibodies can mark cancer cells to be more visible to the immune
system, they are far more speciﬁc than small-molecule drugs; they
are not inherently toxic and are better tolerated. Antibody-based
drugs have achieved remarkable clinical and commercial success.
In 2009, the global market for mAbs was $36.4 billion [2]. In
2011, antibodies generated in excess of $45 billion in sales [3].
More than 40% of this revenue came from anticancer mAbs such
as rituximab, cetuximab, trastuzumab, and bevacizumab. In the
United States alone, the demand for biologics is expected to grow
6.5% a year, while the cancer vaccines market is forecast to grow
at a compounded annual rate of 21% [2]. Some analysts predict that
with the rate of current revenue growth and potential new approv-
als, the global market could reach $58 billion by 2016 [3]. This rateof growth would correspond to 40% of projected drug spending in
2020 on specialty drugs.
1.2. Antibody drugs are generally employed to target extracellular
oncoproteins
Intracellular oncoproteins were thought to be inaccessible by
antibodies, even though there is no evidence with immunotherapy
in mice to support this assumption. As a result, many promising
intracellular targets have only guided development of small mole-
cule drugs, but not antibody-based immunotherapy. The ‘drugga-
ble’ candidates for antibody are perceived to only include the
extracellular oncoproteins. Therefore, several current available
monoclonal antibody drugs are generated only to target cell-sur-
face receptors or soluble proteins for various types of cancers.
1.3. Antibodies can penetrate live human cells
Since the early 1970s, accumulating evidence has suggested
that it is possible for antibodies to access intracellular compart-
ments. Immunologists have demonstrated that antibodies to ribo-
somal proteins are able to penetrate to intranuclear localization in
live human mononuclear cells through Fc receptors-mediated
endocytosis [4,5]. Antibodies could also penetrate viable human
lymphocytes [6]. Immunogenic activity of antibodies against intra-
cellular antigens have been implicated in apoptotic pathways [7,8]
and autoimmune diseases [9,10]. In 1975, it was reported that
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virus 40-transformed (SV 3T3) mouse ﬁbroblasts. The anti-RNA
antibodies retain their anti-antigenic properties and block cellular
proliferation in SV 3T3 [6]. Furthermore, anti-DNA antibodies could
enter nucleus via caveoli-mediated process and subsequently
modulate expression of caveolin and p53 [11]. Recently, tripartite
motif-containing 21 (TRIM21) was shown to be able to mediate
antibody function inside cells by engaging with a potent effecter
mechanism that targets the virus for degradation [12].
1.4. Emerging evidence suggests that immunotherapy can be used to
target intracellular ‘tumor antigens’ for anti-cancer therapy
In 2008, for the ﬁrst time, we reported that it is viable to target
intracellular ‘tumor antigen’ with antibody therapies for anti-can-
cer in mice. mAbs could target intracellular PRL (phosphatase of
regenerating liver) phosphatases, and thus inhibit experimental
metastases [13]. The oncogenic PRL-phosphatases that are hidden
at the inner layer of the plasma membrane or endosomes are often
overexpressed in cancer cells and associated with metastatic pro-
gression of multiple human cancers [14]. Importantly, these PRL-
speciﬁc antibodies could reduce the metastatic tumor burden that
expressed the corresponding intracellular PRL-phosphatase in
nude mice [13]. Conversely, tumors targeted with unrelated anti-
bodies produced no beneﬁcial response. Therapeutic efﬁcacy is
highly dependent on antibody–antigen speciﬁcity. We further ex-
plored this ﬁnding that proteins hidden within cells can be at-
tacked by antibodies. In 2011, we proposed the important
concept of targeting intracellular oncoproteins with antibody ther-
apy or vaccination [15]. Three stable cell lines overexpressing three
distinct intracellular antigens (PRL-3, GFP, middle T) were gener-
ated. Each of these cancer cell lines was injected via the tail vein
into mice to induce experimental metastatic lung tumors. Subse-
quently, the three corresponding antibodies were injected via the
tail vein of mice to inhibit tumor formation. Notably, tumors tar-
geted with unrelated antibodies or tumors without expressing
the corresponding intracellular target showed no therapeutic re-
sponse, suggesting that ‘antibody–antigen’ complexes have to be
speciﬁc in order to achieve therapeutic efﬁcacy. Particularly, the
efﬁcacy seen using a general non-oncogenic reporter (green ﬂuo-
rescent protein) and spontaneous tumor models (polyomavirus
middle T oncoprotein) suggests that this is not only an intrinsic
property of speciﬁc antigens, but a generalized principle that is
applicable to a wide variety of intracellular tumor antigens. Vacci-
nation with each of the intracellular proteins stimulated produc-
tion of speciﬁc antibodies by the host immune system which
then led to speciﬁc tumor regression, resulting in a survival advan-
tage in vaccinated mice. Thus, antibody therapy or vaccination can
both be used to target intracellular oncoproteins for cancer treat-
ment. The therapeutic efﬁcacies from both antibody therapy and
vaccination are similar. In 2012, we generated the ﬁrst chimeric
antibody targeting the PRL-3 intracellular oncoprotein that was
ﬁrst linked to human colorectal cancer liver metastases by Vogel-
stein group in 2001 [16]. The PRL-3 chimeric antibodies could inhi-
bit tumors formed by melanoma cell lines expressing endogenous
PRL-3 protein [17]. To be more clinically applicable, we further
used PRL-3 antibodies to treat FLT3-ITD-associated acute myeloid
leukemia (AML) which often induces PRL-3 overexpression. PRL-3
mAb exerted therapeutic effects in mice carrying PRL-3 expressing
FLT3-ITD cancer cells [18]. Although antibodies have been used in
these mice as mono-therapy, in translating these to the clinical set-
ting, these therapies may potentially also be adjuvant to conven-
tional chemotherapy, radiation, or surgery as well. A study in
2012 reported that antibodies could target intracellular NY-ESO-
1, a widely expressed immunogen in human tumors that is ex-
pressed intracellularly rather than on the surface of cells [19]. Thiseffect is enhanced when combined with chemotherapy. They
showed that intracellular tumor antigens can be captured by mAbs
and engaged in an efﬁcient induction of CD8 T-cell responses, sug-
gesting the possible use of mAbs for passive cancer immunother-
apy. Furthermore, in 2013, another research group has also
reported that targeting the intracellular Wilms tumor 1 (WT1)
oncoprotein with human antibodies reveals therapeutic effects in
mice [20]. WT1 oncoprotein is an intracellular oncogenic transcrip-
tion factor overexpressed in a wide range of leukemias and solid
tumors. This ﬁnding also provides preclinical validation for the
strategy of developing therapeutic mAbs targeting intracellular
oncogenic proteins. A timeline of these studies is illustrated
(Fig. 1) to demonstrate the possibility of immunotherapy targeting
intracellular proteins for anti-cancer therapies.
2. Mechanisms of antibodies targeting intracellular antigens
2.1. In vitro mechanisms
There are various hypotheses to explain the mechanisms of
antibodies targeting intracellular antigens for anti-cancer effect.
In 2008, we showed that antibody could enter live cells via endo-
cytosis which however has no cell-killing effect in culture condi-
tions [13]. This is expected because the in vitro system is not
representative of in vivo complex of biological systems. The
in vitro system is a single cell type grown in medium supple-
mented with 10% FBS in an incubator. In contrast, the in vivo sys-
tem consists of multiple cell types/organs, immune-system, blood
circulation system to achieve ﬁnal cancer cell-killing effect. There-
fore, in vitro cell-culture system is unable to mimic in vivo com-
plexity. In 2011, Ferrone elegantly proposed three possible
mechanisms in his Perspective [21] on our study for the antitumor
activity of intracellular tumor antigen (TA)-speciﬁc mAbs. Intracel-
lular TAs might: (i) interact with mAbs that have been internalized
(through a B-cell mediated mechanism) by tumor cells, which are
then destroyed, (ii) migrate to the cell membrane and bind to
mAbs on the surface, and the TA-mAb complex is recognized by
Fc receptors on NK cells which carry out antibody-dependent cyto-
toxicity, or (iii) be shed into the microenvironment or circulation to
form complexes with circulating mAbs. We hypothesized that
these TAs are shed into blood circulation due to cell lysis or uncon-
ventional secretion [22]. Although soluble tumor antigens may
potentially neutralize the therapeutic effect of antibodies, the com-
plex could then be taken up by dendritic cells, which process the
TAs and present the resultant TA peptides to cognate T cells. Acti-
vated T cells then mediate tumor-cell killing. Cancer antigens
(regardless extra- or intra-cellular location) are generally more
concentrated near the cancer mass due to continuous shedding;
the antigen–antibody complexes may induce more localized im-
mune responses to the cancer cells by recruiting lymphocytes
and other components of the immune system. This could be part
of the mechanism underlying the therapeutic effects of antibodies
against intracellular oncoproteins.
2.2. In vivo mechanisms
We investigated possible in vivo mechanisms by scoring immu-
notherapeutic efﬁcacies based on our studies [13,15,17,18] (Fig. 1,
labelled with ⁄) using more than 4000 mice from 8 different mouse
strains (Table 1) and identiﬁed several key factors that could con-
tribute to therapeutic efﬁcacy. (1) The Antigen-antibody speciﬁc
interaction is critical for therapeutic effect. Tumors targeted with
unrelated antibodies produced no beneﬁcial response, suggesting
that the antibody is dependent on its speciﬁc antigen for efﬁcacy.
(2) B-cells & NK cells (but not T-cells) are required for therapeutic
efﬁcacy. We showed therapeutic efﬁcacy in a nude mouse model
Fig. 1. A timeline of 6 studies demonstrating viability of targeting intracellular proteins with immunotherapy. Four studies (indicated by ⁄) were reported from our
laboratory. Numbers of mice used in these studies are in Table 1.
Table 1
Using 8 different mouse strains, the results illustrate that the therapeutic efﬁcacy ( ) depends on the presence ( ) of B-cells.
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(Scid) mouse model (B- and T-cell deﬁcient). Furthermore, thera-
peutic effects were seen in C57BL6 wild type but not in muMT
mice (B-cell deﬁcient). Both Scid mice and muMT mice have no
B-cells and do not show therapeutic effects [15,23]. (3) While the
full Fc fragment is essential, subtypes of antibodies are not critical.
We used several different subtypes of antibodies (IgG1, IgG2a,
IgG2b, rabbit antibodies) to target intracellular ‘tumor speciﬁc’
antigens. The therapeutic responses are highly dependent on the
expression levels of the respective targets, but independent on
subtypes of the antibodies. Furthermore, when we used PRL-3
mini-body where the CH1 and CH2 domains are absent from Fc
fragment, we observed little therapeutic effect, suggesting that
the complete Fc fragment is essential for antibody response
(unpublished data). (4) Complement 5 may not be involved. We next
used MMTV-PymT transgenic mice that are commonly used as
excellent spontaneous tumor models for decades by the cancer re-
search community. MMTV-PymT transgenic mice carry the mT
intracellular DNA viral oncoprotein under the transcriptional con-
trol of the mouse mammary tumor virus promoter/enhancer as a
model of oncogene-induced mammary tumorigenesis [24]. The
mT expression is detected at high levels in mammary glands, andthe expression of mT oncogene is sufﬁcient for mammary epithe-
lial cell transformation [25]. All untreated female carriers (geno-
type +/) develop palpable mammary adenocarcinomas at the
age of 2–3 months. Untreated mice carried marked breast tumors
and multiple lung tumors, whereas 83.4% (15/18) of mT anti-
body-treated mice showed marked reduction in the formation of
metastatic breast tumors when examined at 12–13 weeks [15].
These results suggest that the extensive repression of spontaneous
tumor formation could be achieved by treating MMTV-PymT mice
with mT antibody alone. MMTV-PymT mice were derived from the
parental FVB/NJ background, which fail to secrete complement 5
due to a 2-bp deletion in the Hc gene, causing a truncation of the
protein [26,27]. Since immunotherapeutic efﬁcacies were still ob-
served in these complement 5 deﬁcient MMTV-PymT mice [15],
the results suggest that complement 5 may not be involved in
the pathway. Our studies collectively suggest there are multiple
mechanisms operating in vivo. On one hand, the oncoproteins
can be recognized either intracellularly or extracellularly after
externalization by unconventional secretion, cell lysis, or being dis-
played as part of major histocompatibility complex (MHC) mole-
cules. On the other hand, speciﬁc antibody–antigen interaction
will ultimately trigger the host immune system which may engage
Fig. 2. Various strategies by which immunotherapy may be used against tumors. Although antibodies may not be effective against encapsulated mature primary tumors (A),
they can target micro-metastases (B) and circulating cancer cells. Introducing antibodies into the circulation (C) may be effective alongside conventional therapy.
C.W. Hong, Q. Zeng / FEBS Letters 588 (2014) 350–355 353NK cells, B cells or T-cells. In summary, speciﬁc interactions be-
tween intracellular oncoproteins with antibodies will trigger a
range of host immune responses that collectively manifest the
therapeutic effect on cancer cells.
3. Clinical perspectives
3.1. Select ‘tumor speciﬁc’ therapeutic targets for immunotherapy
One of the most crucial challenges in the development of anti-
cancer treatments is to ﬁnd a speciﬁc ‘tumor antigen’ that is suit-
able for immunotherapy. It is essential to predict potential toxicity
by carefully analyzing the expression levels of the candidate ‘tu-
mor antigen’ in normal tissues. A desirable ‘tumor antigen’ should
be highly expressed in cancer cells relative to normal cells, as ideal
anti-cancer therapeutic agents should speciﬁcally target cancer
cells while leaving normal tissues unharmed. Currently, only a
few limited cell surface proteins have been selected for antibody
therapies. Our unconventional concept prompts an evaluation of
a wide spectrum of tumor-speciﬁc intracellular oncoproteins
(including mutated oncoproteins, such as Ras and EGFR or viral
proteins) as possible targets for mAb therapy or vaccination for hu-
man diseases. Oncogenic mutations commonly contribute to mul-
tiple human cancers and are often detected in intracellular
proteins or the intracellular domains of cell surface proteins. Our
recent research suggests an unconventional concept that intracel-
lular oncoproteins can be targeted by therapeutic antibodies or
peptide vaccination [15]. Generating antibodies against those
mutations could speciﬁcally target cancer cells expressing respec-
tive mutated targets while sparing normal tissues. However, this
strategy depends on the development of antibodies that only react
with mutant but not the wild-type proteins. So far, hundreds of
possible oncotargets have been found to have one or more muta-
tions, which are listed at this website: http://share.gene.com/
mutation_classiﬁcation/cancer.variants.txt. Making antibodies
one by one in vitro speciﬁcally against each point mutation is
impractical, especially considering the high costs for existing anti-
body therapy.
Since modern technology can easily identify patients whose tu-
mors are associated with a speciﬁc oncogenic mutation, peptides
corresponding to mutated epitopes could be designed. An animalmodel is essential to pre-clinically evaluate the immunogenicity
for each peptide. Vaccines can elicit long-lived immunity where
the tumor speciﬁc antigens (or recombinant peptides) are used
to trigger patients’ immune system to make their own antibodies
and activate cytotoxic T lymphocytes (CTLs) against mutated tar-
gets. Targeting oncoproteins with speciﬁc mutations is a precise
approach against cancer cells since the mutated proteins only spe-
ciﬁcally exist in cancer cells but not in normal cells/tissues, hence
minimizing side effects. Such epitope-based peptide vaccination is
more rapid and economical than antibody development.
Our untraditional concept of immunotherapy presents a more
speciﬁc strategy of targeting internal cellular proteins than using
small-molecule inhibitors. The immunotherapies would target
intracellular targets not only in cancer cells but also in cancer stem
cells. Since cancer stem cells play important roles in disease recur-
rence and metastatic spread, targeting cancer stem cells will be
particularly effective in treating cancer. As oncogenic mutations
in stem or progenitor cells are believed to be part of the process
in the development of cancer stem cells, antibodies against mutate
oncoproteins such as K-Ras G12 V, G13D, and EGFR L858R will
likely be able to target cancer cells and cancer stem cells [28,29]
but keeping host normal tissues unharmed. The effect of intracel-
lular tumor-speciﬁc antibodies on cancer stem cells may lower
the rate of disease recurrence or metastatic spread.
If one looks past the long-standing dogma that antibodies only
react against extracellular antigens, one would immediately appre-
ciate a vast new array of intracellular oncoproteins as possible
cancer therapeutic targets, thus realizing the full potential
immunotherapies against both extracellular and intracellular
oncotargets. Herein, we anticipate exploring buried intracellular
treasures and vastly expanding the list of intracellular targets as
candidates for immunotherapy.
3.2. The applications of antibody therapeutics
Metastasis confers a poor prognosis to cancer patients. Anti-
body therapies provide speciﬁc treatments against speciﬁc onco-
targets. We proposed that antibodies are unlikely to be able to
penetrate mature primary tumors which are generally protected
with capsules (Fig. 2A), yet the antibody therapies are possible to
markedly reduce metastatic tumor. This is because antibody
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lating cancer cells (Fig. 2C). Oncologists can remove visible/mature
primary tumors by surgery. We suggest that introducing antibod-
ies into patient’s circulation (Fig. 2C) before or after surgery would
be the key to reduce the risk of cancer metastasis and relapse. It is
anticipated that the PRL-3 humanized antibody is likely to have
broad applications in limiting the progression of different types
of PRL-3 positive cancers, particularly in malignancies such as gas-
tric cancers, lung cancers and AML which often relapses quickly.
Clinical beneﬁt will be more easily observed in more aggressive
malignancies in initial clinical studies of PRL-3 positive patients.
Although our understanding of how PRL-3 antibodies inhibit
PRL-3-positive tumors in vivo is not well understood, it should
not deter clinical usage. Many drugs, including trastuzumab for
breast and esophagogastric cancers, are used successfully in clini-
cal practice without detailed understanding of their mechanisms
of action.
3.3. Vaccine can be more prominent than antibody therapy
Existing antibody therapy for cancer treatment is very costly.
We hope that our research will pave the way for cancer vaccination
to become a mainstream cancer treatment that will be both effec-
tive and affordable. In patients with a strong family history of can-
cer, immunization of young susceptible family members with an
antigen associated with the familial cancer could prime the im-
mune system against tumor cells expressing that antigen and
may prevent cancer before it develops.
3.4. Drug development prioritization
Unfortunately, cancer immunotherapy and vaccine develop-
ment is limited by many factors, in particular funding constraints.
Nearly any mutated or abnormally expressed protein in cancer
cells can potentially serve as therapeutic targets, and so the num-
ber of possible targets dwarfs the key antigens that can be of cur-
rent research interest. It is important to prioritize research targets
and opportunities to maximize the beneﬁt achievable with limited
resources. The National Cancer Institute has conducted an immu-
notherapy agent workshop in 2007, ranking agents based on their
potential efﬁcacy in cancer therapy. Of the top 50 cancer antigens
by prioritization, 29 of them were only expressed inside the cell; of
the top 10 antigens, 6 of them were expressed intracellularly [30].
These antigens were selected based on criteria such as therapeutic
function, immunogenicity, role of the antigen in oncogenicity, and
speciﬁcity. The majority of these intracellular antigens have been
passed over due to their intracellular location. We have demon-
strated that vaccination with an intracellular ‘tumor antigen’ [15]
stimulated production of speciﬁc antibodies by the host, which
then led to tumor regression. The evidence demonstrating the via-
bility of targeting these antigens may lead to reprioritization of fu-
ture research efforts to more promising oncoproteins and increase
availability of new speciﬁc cancer therapies. Subsequently, there
has been additional work in PRL-3 vaccines and the development
of antibodies targeting other intracellular oncogenes. Many high
priority cancer targets have been relatively neglected due to their
intracellular location. This unconventional concept highlights the
viability of targeting these intracellular proteins and greatly ex-
pands the range of possible therapeutic targets.
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